Chromium Picolinate Shows Clinical Benefits in Diabetes Management

A peer-reviewed analysis on chromium picolinate (Nutrition 21, Inc.) has been published in Diabetes Technology & Therapeutics. The analysis confirms that chromium picolinate is effective in improving glycemic control and normalizing lipid levels in people with type 2 diabetes. The review analyzed 15 clinical studies of people with diabetes. All studies showed chromium picolinate produced benefits in one or more standard measures of diabetes management, with no adverse events reported. The studies examined people with type 2, type 1, gestational and corticosteroid-induced diabetes. Although glycemic control varied by trial, all 15 trials showed improvements in one or more measurements of glycemic control, including fasting glucose, postprandial glucose, fasting insulin, postprandial insulin, glycated hemoglobin or insulin sensitivity. The authors concluded the greater bioavailability of chromium picolinate compared to other forms of chromium may explain its comparatively significant superior effects on glycemic and lipidemic control.

For further information: 914-701-4500.